Salarius Pharmaceuticals (SLRX) News Today → Biden replacement revealed? (From Paradigm Press) (Ad) Free SLRX Stock Alerts $0.50 -0.03 (-5.65%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSalarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Up 7.5%americanbankingnews.com - May 2 at 2:24 AMSLRX Pursues Important Goalfinance.yahoo.com - April 2 at 1:44 PMWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Datamsn.com - March 27 at 1:54 AMWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarketmsn.com - March 25 at 11:52 AMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 23 at 8:07 AMSalarius: Q4 Earnings Snapshotsfgate.com - March 22 at 4:56 PMSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 22 at 4:05 PMQuoin stock craters 47% on public offering after rallying in prior sessionmsn.com - March 5 at 2:32 PMQuoin stock soars 60% on FDA update for ichthyosis drugmsn.com - March 4 at 12:43 PMSalarius Pharmaceuticals Implements Cost-savings Measuresmarkets.businessinsider.com - February 22 at 1:52 PMSalarius's CEO David Arthur steps downmsn.com - February 22 at 8:52 AMSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expensesfinance.yahoo.com - February 22 at 8:52 AMSalarius Pharmaceuticals Inc (SLRX)uk.investing.com - February 9 at 12:58 AMSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degradersfinance.yahoo.com - January 16 at 1:35 PMSquare Pharmaceuticals Ltd.wsj.com - January 13 at 3:02 PMInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollmentfinance.yahoo.com - January 3 at 9:32 AMSLRX Continues Work as it Seeks Alternativesfinance.yahoo.com - November 10 at 4:03 PMSalarius Pharmaceuticals Inc SLRXmorningstar.com - November 8 at 8:37 AMSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Programfinance.yahoo.com - November 7 at 10:25 AMSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsbizjournals.com - August 10 at 6:57 PMSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - August 10 at 6:57 PMSLRX Pursuing Strategic Alternativesfinance.yahoo.com - August 9 at 3:15 PMmarketbeat.com - August 8 at 4:08 PMWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Targetbenzinga.com - July 11 at 5:51 PMSLRX Continues Cancer Fight with Phase I Trial Approvalfinance.yahoo.com - July 11 at 5:51 PMSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Applicationmarketwatch.com - July 11 at 12:51 PMSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patientsfinance.yahoo.com - July 11 at 12:51 PMSalarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congressfinance.yahoo.com - June 12 at 7:37 PMSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rulesmarketwatch.com - May 17 at 4:13 PMSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 8:30 PMSalarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - May 12 at 9:22 AMRecap: Salarius Pharmaceuticals Q1 Earningsmsn.com - May 11 at 11:16 PMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Updatefinanznachrichten.de - May 11 at 1:15 PMSalarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - May 11 at 8:14 AMSalarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhoodmsn.com - May 9 at 9:48 AMFDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcomafinance.yahoo.com - May 9 at 9:48 AMSalarius Pharmaceuticals, Inc. (SLRX)uk.finance.yahoo.com - May 2 at 2:41 PMSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164finance.yahoo.com - May 1 at 9:14 AMSalarius Pharmaceuticals (FRA:FP1) Price Target Decreased by 7.80% to 55.93msn.com - April 24 at 11:43 PMSalarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meetingfinance.yahoo.com - April 20 at 11:06 AMSalarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conferencefinance.yahoo.com - April 4 at 6:07 PMDiamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023finance.yahoo.com - April 4 at 1:06 PMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinanznachrichten.de - March 27 at 11:57 AMSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 27 at 11:57 AMSalarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meetingfinance.yahoo.com - March 15 at 1:27 PMSalarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposiafinance.yahoo.com - March 7 at 9:11 AMSalarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texasfinance.yahoo.com - February 16 at 10:09 AMSalarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summitfinance.yahoo.com - January 27 at 8:39 AMThinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ?morningstar.com - January 22 at 1:10 PMmarketbeat.com - January 19 at 3:08 PM Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report SLRX Media Mentions By Week SLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRX News Sentiment▼0.000.42▲Average Medical News Sentiment SLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRX Articles This Week▼10▲SLRX Articles Average Week Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLR News Today SNOA News Today CYTO News Today CWBR News Today CNSP News Today MBIO News Today DRMA News Today ONCO News Today SXTP News Today NTBL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
